James Shehan, JD, chair of regulatory practice at Lowenstein Sandler, LLP, discusses how the FDA plans to address citizen petitions that impede market entry of competitive products.
Transcript
How does the FDA plan to crack down on citizen petitions that are used to delay market entry of competitor products?
When we talk about the use of citizen petitions to impede or potentially affect the entry of competitive products in the marketplace, we’re talking about a narrower class of citizen petitions for which Congress actually enacted a separate provision of the statute, 505q. What that essentially says is there’s a citizen petition that is potentially going to delay a generic product, either an [Abbreviated New Drug Application, ANDA], a 505(b)(2), or 351k biosimilar, that FDA has to make decisions on those in an expedited fashion.
The FDA recently issued some guidance about changing the way that it views and reviews citizen petitions that come in to delay the entry of a generic drug into the market. What’s essentially said is given a lot more detail on how it will view those types of petitions and it has issued a set of criteria that it will look at in deciding whether one of these petitions has a primary purpose of trying to delay generic competition.
The agency has also said, if it makes that determination, that it’s going to refer the matter to the Federal Trade Commission for possible investigation of anticompetitive activities. Which FDA has done on at least 1 occasion regarding Shire and its vancomycin product where there were a number of citizen petitions submitted over a period of years.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.